Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1219-1225

  Lew, Kaung Yuan ^a   Ng, Tat Ming ^b   Tan, Michelle ^b   Tan, Sock Hoon ^b   Lew, Ee Ling ^b   Ling, Li Min ^b   Ang, Brenda ^b   Lye, David ^b,c   Teng, Christine B ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

ASP; Imipenem; Meropenem

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEPHALOSPORIN; COTRIMOXAZOLE; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CHRONOTHERAPY; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; DEMOGRAPHY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG PROGRAM; DRUG SAFETY; DRUG WITHDRAWAL; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROTOXICITY; NONHUMAN; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SPECIES ENDEMICITY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTIONS; DIARRHEA; DRUG EFFECTS; DRUG THERAPY; DRUG UTILIZATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDEMIC DISEASE; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DRUG THERAPY; DRUG UTILIZATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDEMIC DISEASES; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84926485889     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku479     Document Type: Article

References (25)

1. Muscedere JG, Shorr AF, Jiang X et al. for the Canadian Critical Care Trials Group. The adequacy of timely empiric antibiotic therapy for ventilatorassociated pneumonia: an important determinant of outcome. J Crit Care 2012; 27: 322.e7-14.
2. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008; 47 Suppl 1:S3-13.
3. Shlaes DM, Gerding DN, John JF Jr et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-99.
4. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 2007; 45 Suppl 3: S177-83.
5. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
6. Masterton RG. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents 2009; 33: 105-10.
7. Drew RH, White R, MacDougall C et al. for the Society of Infectious Diseases Pharmacists. Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Pharmacotherapy 2009; 29: 593-607.
8. Rhee JY, Kwon KT, Ki HK et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009; 31: 146-50.
9. Hall WH, Ramachandran R, Narayan S et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004; 4: 94.
10. Alvarez-Lerma F, Alvarez B, Luque P et al. for the ADANN Study Group. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006; 10: R78.
11. Kollef MH, Morrow LE, Niederman MS et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129: 1210-8.
12. Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40: 32-40.
13. Rello J, Vidaur L, Sandiumenge A et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32: 2183-90.
14. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients. Infection 2011; 39: 319-25.
15. De Waele JJ, Ravyts M, Depuydt P et al. De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality? J Crit Care 2010; 25: 641-6.
16. Apisarnthanarak A, Bhooanusas N, Yaprasert A et al. Carbapenem de-escalation therapy in a resource-limited setting. Infect Control Hosp Epidemiol 2013; 34: 1310-3.
17. Davey P, Brown E, Fenelon L et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005; issue 4: CD003543.
18. Carling P, Fung T, Killion A et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24: 699-706.
19. Climo MW, Israel DS, Wong ES et al. Hospital-wide restriction of clindamycin:effect on the incidence of Clostridium difficile-associated diarrhoea and cost. Ann Intern Med 1998; 128: 989-95.
20. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 2003; 54: 104-8.
21. McNulty C, Logan M, Donald IP et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997; 40: 707-11.
22. Aldeyab MA, Kearney MP, Scott MG et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012; 67: 2988-96.
23. Ng TM, Teng CB, Lye DC et al. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2014; 35: 49-55.
24. Bailey TC, Ritchie DJ, McMullin ST et al. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy 1997; 17: 277-81.
25. Heenen S, Jacobs F, Vincent J. Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often? Crit Care Med 2012; 40: 1404-9.